Treatment of cardiac arrhythmia via re-expression of TBX5 (gene therapy) Cardiovascular disease is the number one cause of death worldwide. Scientists at the University Medical Center Göttingen developed a gene therapy (TBX5 re-expression) for use in the prevention or therapeutic treatment of a ventricular heart disease and associated complications (e.g. cardiac arrhythmia and sudden cardiac death).
Method for increasing the safety of tissue engineered products for clinical use Regenerative medicine is the replacement of diseased tissues with tissue engineered products (TEPs). Stem cells have emerged as the most important source for TEPs. However they carry the risk of uncontrolled cell growth. To solve this problem the present invention uses radiation for mitotic inactivation without loss of function.
Iron-paraCEST-MRI-Contrast-Agents We developed first row transition metal ions (i.e. Fe/ iron) supported by macrocyclic ligands to provide alternatives to lanthanide contrast agents for MRI- thus NOT using gadolinium. The tripodal Schiff base ligands provide water-soluble coordination complexes with i.e. iron, providing signal contrast in MRI.
Restoration of DFNB83 deafness Our technology restores hearing with a virus-mediated delivery of CaBP2 for a gene-therapy of DFNB83. A one-vector system for CaBP2 (Ca+2 binding protein 2) is delivered directly into the cochlea. In a CaBP2 knock-out mouse model we showed transduction of inner hair cells and restoration of hearing.
Pharmacologically controlled vector for CNS gene therapies Gene therapies are irreversible and not controlable in case of side effects. We offer a pharmacologically controlled one-vector expression system of a therapeutic factor (i.e. GDNF) with zero background expression, based on mifepristone (Mfp)-Gene Switch system, for the therapy of neurological diseases.
Targeted Demethylating Gene Therapy of Fibrosis All-in-one construct dCas9-TET3CD-(target gene)-sgRNA for targeted fibrosis therapy through demethylation of the genes RASAL1, LRFN2, KLOTHO (i.e. in heart, kidney, liver, lung, cancer). Normal re-expression of these genes has been achieved successfully in vitro and in vivo as well as a reduction of fibrosis.
Prevention of Fibrosis and Organ Protection Prevention of Fibrosis and Organ Protection by preconditioning cells via ARNT regulation, i.e. via low-dose tacrolimus, GPI-1046, LB100 or via gene-therapy.
1-vector otoferlin DFNB9 gene therapy Due to the large OTOF size a one-vector delivery has remained challenging.Our technology: Gene-therapy of the otoferlin gene (OTOF) with overloaded AAV virus mediated delivery into the cochlea. In vivo proof-of-concept successfully achieved.
New Genetic Test for Bleeding disorders in Dogs Scientists at the University of Veterinary Medicine Hanover, Germany developed a new test for a genetic defect causing bleeding disorders in dogs. It allows breeders to improve targeted mating by omitting genetic carriers to avoid genetic diseases in offsprings. This is especially important for autosomal recessive mutations.
Improved marker vaccine against classical swine fever Scientists at the University of Veterinary Medicine Hanover developed a new marker vaccine for classical swine fever based on chimeric pestiviruses with improved DIVA (Differentiating Infected from Vaccinated Animals) properties. The used marker Erns is a chimeric sequence of two different and remotely related pestiviruses.
Leucodistrophy-Repositioning: Laquinimod for Zellweger-Syndrome Zellweger Syndrome spectrum, an orphan disease, is a peroxisomal biogenesis disorder with no treatment currently available. We offer the use of the clinically known Laquinimod (developed for multiple sclerosis) for the therapy of Zellweger Syndrom, for which we achieved successfully an in vivo proof-of-concept.
Bio-engineered neuronal organoids from human stem cells Scientists at the University Medical Center Göttingen, Germany developed a reproducible, robust and fully defined method for serum-free production of human bio-engineered neuronal organoids (BENOs) from stem cells. This new method will allow for reproducible production of oganoids with fully functional neuronal network activity.
New bifunctional Prodrugs with cleavable linker for targeted tumor therapy (ADC) Scientists at the University of Göttingen in Germany developed new and highly potent drugs with cleavable chemical linkers to develop tumor specific antibodies for selective tumor therapy (ADC). The soluble prodrugs are activated into highly cytotoxic drugs only in targeted tumor cells.
GMP-compatible Methods for producing tissue-engineered human heart muscle from stem cells Heart tissue engineering using stem cells is a recently developed technique to construct a three dimensional cell structure from cardiomyocytes or directly from progenitor cells. Scientists at the University of Göttingen developed two new and fully defined methods for serum-free production of engineered human heart muscles.
New enzymatic carbon dioxide capture from exhaust fumes. Die Reduktion von klimaschädlichen CO2 ist eine der dringendsten Aufgaben für eine umweltfreundliche und nachhaltige Energiegewinnung. Biotechnologische Ansätze haben hier einen hohen Stellenwert erlangt. Wissenschaftler der Universität Göttingen entwickelten einen neuen Biokatalysator zur CO2-Fixierung.
New Genetic Test for Shar-Pei Autoinflammatory Disease (SPAID) Shar-Pei Autoinflammatory Disease (SPAID) is a complex inflammatory disease. Typical signs are recurrent bouts of fever, inflammations of the ear, arthritis and a reddened skin. The dogs can also develop amyloidosis. Scientists at the University of Veterinary Medicine Hannover developed a genetic test for SPAID predisposition.
Monoclonal antibodies against biotinylated AP-tag / Avi Tag Scientists at the University Göttingen developed a monoclonal antibody against a biotinylable peptid (Epitope-Tag) called AP-tag or Avi Tag. This small peptide served as a substrate mimic for biotin ligase (BirA). Anti-AP antibodies are useful tools in the analysis of AP-tag fusion proteins.
Prodrugs/drugs for a selective ADEPT/ADC tumor therapy Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs. Selectivity is achieved by antibody tumor targeting. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site.
Humanized anti-CCR2 Antibody for the Therapy of MS and RA Scientists of the University of Göttingen and of the University of Regensburg developed in collaboration a proprietary anti-CCR2 antibodies for the therapy of Multiple Sclerosis (MS) and potentially Rheumatoid Arthritis (RA).The lead candidate Doc-2 has been humanized in collaboration with the MRC Technologies. It targets the CCR2 receptor and modulates the autoimmune process through depletion of CCR2+ monocytes.
Prevention and Treatment of Mastitis with Probiotics Mastitis continues to be the most important economic risk for dairy farmers. Current treatment rely heavily on antibiotics, which is costly and frequently ineffective due to increased spread of antibiotic resistance. Scientists at the University of Applied Sciences and Arts Hannover developed a probiotic and protective teat dip.
Drug Delivery Vehicle/Plattform into brain Scientists of the University of Göttingen developed a novel vehicle for the targeted delivery of drugs into the brain parenchyma, particularly useful for the delivery of biologics, like e.g. proteins or antibodies.
Animal model für sporadic Alzheimer's Disease New transgenic mouse model for sporadic Alzheimer's Disease. It does not have any mutation and it shows neurological deficits by transgenic over-expressing a major form of amyloid beta peptides (N-truncated Abeta 4-42) found in the brain of AD patients.
Specific DPP8 and/or DPP9 inhibitors Peptidases are essential for many biological processes and are therefore intensively studied within the research community. Scientists at the University of Göttingen developed new and for the first time specific inhibitors of dipeptidyl peptidase 8 and 9, without inhibiting other members of the dipeptidyl peptidase 4 family.
New therapy for amyotrophic lateral sclerosis Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease is one of the most common degenerative neuromuscular diseases worldwide and characterized by rapidly progressive weakness and muscle atrophy throughout the body. Scientists at the University of Göttingen developed a new neuroprotective therapeutic approach for ALS.
Therapy of Alzheimer's Disease with an antibody against oligomeric pyro-Glu-Abeta peptides Scientists at the University of Göttingen developed a novel, proprietary antibody for the therapy and/or diagnosis of Alzheimer's Disease (AD) through the targeting of specifically pyro-Glu-Amyloid beta peptides.
New animal model for Gastrointestinal Stromal Tumor Gastrointestinal stromal tumor (GIST) is one of the most common mesenchymal tumors of the gastrointestinal tract. GISTs occur in 10-20 per one million people. Thus, GIST has been named as an orphan drug disease. Scientists at the University of Göttingen developed a new animal drug screening model for GIST.
Improved PCR Diagnostic for detection of Paratuberculosis (or Johne’s disease) Paratuberculosis or Johne's disease is a contagious, chronic and also fatal bacterial infection, which generally occurs early in life. The disease can exist undetected in a herd for many years. Scientists at the University of Göttingen developed an improved PCR diagnostic test for fast and early detection of Paratuberculosis.
New animal model for arthritic diseases Arthritic diseases are conditions involving damages to the joints and/or cartilage. A primary form of arthritis is for example rheumatoid arthritis, which affects over 21 million people worldwide. Scientists at the University of Göttingen have developed a new animal drug screening model for arthritic diseases.
New enzymes for transformation of fatty acids Oils and fats are the most important raw materials for the chemical industry. Modern biotechnology methods are now extensively applied to fatty acid compounds for selective functionalization of alkyl chains. Scientists at the University of Göttingen isolated and developed new enzymes for strategic transformation of fatty acids.
Culture Collection of Algae of Göttingen University (SAG) The Culture Collection of Algae at the Georg August University Göttingen is one of the five largest collections of living microscopic algae. Founded in 1954, the SAG collection today holds around 2.250 strains from almost all evolutionary lineages of algae and cyanobacteria (1202 named species from 521 genera), mostly isolated from freshwater or terrestrial habitats.
Antibodies for Licensing Scientists at the University of Göttingen have developed a variety of monoclonal antibodies, which are used for research purposes, but also find applications in the development of diagnostic tests and therapeutic solutions. Here you will find a list of all antibodies that currently are available for licensing. Details
